← Browse by Condition

Medical Condition

parkinson disease

Total Trials

50

Recruiting Now

50

Trial Phases

Phase 1, Phase 4, Phase 2

Parkinson's disease research has expanded from symptomatic management (dopaminergic drugs, DBS) toward neuroprotective and disease-modifying strategies targeting alpha-synuclein aggregation β€” the protein implicated in Lewy body pathology. Prodromal biomarker studies now aim to identify patients years before motor symptoms appear, when intervention may be most effective.

Trials test alpha-synuclein antibodies (prasinezumab, cinpanemab), GBA1 gene therapy, adaptive deep brain stimulation (aDBS), GLP-1 agonists (liraglutide, semaglutide), and nilotinib for neuroprotection. Skin biopsy and cerebrospinal fluid alpha-synuclein assays are emerging as enrollment biomarkers.

Disease-modifying trials often restrict enrollment to early-stage patients (Hoehn & Yahr 1β€“2.5) within a few years of diagnosis to capture sufficient disease duration for benefit detection.

Frequently Asked Questions — parkinson disease Clinical Trials

How many clinical trials are currently recruiting for parkinson disease?

ClinicalMetric currently tracks 50 actively recruiting clinical trials for parkinson disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 50. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for parkinson disease?

parkinson disease research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 3 (2 trials), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a parkinson disease clinical trial?

Eligibility criteria for parkinson disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

2

Phase 2

3

Phase 3

2

Phase 4

2

Top Sponsors

Xiangya Hospital of Central South University 3 trials

Insel Gruppe AG, University Hospital Bern 3 trials

The Cleveland Clinic 2 trials

Abant Izzet Baysal University 2 trials

Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2 trials

Recruiting Clinical Trials

The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions

University of Cambridge

Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease

Anhui Medical University

NCT07371338 Phase 1

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

Innopeutics Corporation

Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

Jorge Gonzalez-Martinez

Chinese PD Registry

Xiangya Hospital of Central So...

NCT07138560 Phase 4

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

The Cleveland Clinic

Molecular and Functional Imaging in Monogenic PD.

University of Exeter

NCT06629389 Phase 2

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Laboratorio Elea Phoenix S.A.

Long-Term Behavioral and Cognitive Outcomes of Deep Brain Stimulation in Patients With Parkinson's Disease

Fondazione IRCCS Ca' Granda, O...

The Effect of Spinal Mobilization on Respiratory Parameters in Parkinson's Disease Patients

Turkey (Türkiye)

Abant Izzet Baysal University

Neural Control of Breathing in Parkinson's Disease

Radboud University Medical Cen...

Natural History Study of Synucleinopathies

United States, Argen...

NYU Langone Health

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing

Oregon Health and Science Univ...

High-intensity Functional Training on Functional and Cognitive Performance in People with Parkinson's Disease.

Fundacion Para La Investigacio...

Cognitive Testing Online in Parkinson's Disease

McGill University

Serum Biomarkers in Parkinson's Disease at Different Stages

Fondazione Policlinico Univers...

NCT06765668 Phase 4

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Impax Laboratories, LLC

NCT06976268 Phase 2, Phase 3

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Biohaven Therapeutics Ltd.

Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease

Insel Gruppe AG, University Ho...

SpiroGym App-Aided Cough Rehabilitation

General University Hospital, P...

Physical Activity on Neuroinflammation in Parkinson's Disease

IRCCS National Neurological In...

NCT05152394 Phase 1

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease

United States, Greec...

The Foundation for Orthopaedic...

NCT07156773 Phase 2

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

Guangzhou Novaken Pharm Co., L...

Short- and Long-term Behavioral, Cognitive and Motor Outcomes of Frameless Deep Brain Stimulation in Patients With Parkinson's Disease: a Prospective Observational Study

Fondazione Policlinico Univers...

Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

University Hospital, Bordeaux

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Insel Gruppe AG, University Ho...

Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease

University of North Carolina, ...

Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life

Centre Hospitalier Régional d'...

Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range

University Hospital, Bordeaux

NCT04706910 Phase 3

18F-DOPA II - PET Imaging Optimization

University of Alberta

Training of Nursing Home Professionals and Quality of Life of Residents With Parkinson's Disease

University Hospital, Grenoble

Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD

University of Florida

SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease

Czechia, Switzerland

Insel Gruppe AG, University Ho...

World Data on Ambroxol for Patients With GD and GBA Related PD

Shaare Zedek Medical Center

Minimal Clinically Important Difference of the Box and Block Test in Parkinson

Turkey (Türkiye)

Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases

Austria, Germany, Is...

Kliniken Beelitz GmbH

Spinal Cord Stimulation for Parkinson's Disease Rehabilitation

University of Louisville

Chinese FPD Registry

Xiangya Hospital of Central So...

CsDCS on Functional Mobility in Parkinsons Disease

Universidade Federal de Pernam...

Real-Time Levodopa Level Monitoring in Parkinson Disease

University of California, San ...

Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

Vanderbilt University Medical ...

Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease

The Cleveland Clinic

TMS-related Measures as Biomarker of Cognitive Impairment in PD

Azienda Sanitaria Universitari...

Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices

IRCCS Centro Neurolesi Bonino ...

Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait

Medical University of South Ca...

Use of CereGate Therapy for Freezing of Gait in PD

Chinese DENOVO PD Registry

Xiangya Hospital of Central So...

Influence of Autonomy on Motor Learning in People With Parkinson's Disease

National Taiwan University Hos...

Patient-Specific 3D Action Observation Training in Parkinson's Disease

Turkey (Türkiye)

Abant Izzet Baysal University

Related Conditions

rem sleep behavior disorder (3) parkinson s disease (2) dementia (2) alzheimer disease (2) stroke (2) neurodegenerative diseases (2) multiple system atrophy (2) freezing of gait (2) parkinson disease disorder (1) parkinson (1) rem behavior disorder (1) rem sleep behavior disorder irbd (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology